Mark Anthony Mccamish Sells 8,301 Shares of Forty Seven Inc (NASDAQ:FTSV) Stock

Forty Seven Inc (NASDAQ:FTSV) insider Mark Anthony Mccamish sold 8,301 shares of Forty Seven stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $11.04, for a total value of $91,643.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Mark Anthony Mccamish also recently made the following trade(s):

  • On Monday, May 20th, Mark Anthony Mccamish sold 16,500 shares of Forty Seven stock. The shares were sold at an average price of $12.10, for a total value of $199,650.00.
  • On Thursday, April 18th, Mark Anthony Mccamish sold 16,500 shares of Forty Seven stock. The shares were sold at an average price of $18.12, for a total value of $298,980.00.

NASDAQ:FTSV opened at $10.80 on Wednesday. The firm has a 50-day moving average of $12.62. Forty Seven Inc has a 12 month low of $9.90 and a 12 month high of $23.83. The stock has a market capitalization of $340.26 million and a price-to-earnings ratio of -2.88.

Forty Seven (NASDAQ:FTSV) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Equities research analysts expect that Forty Seven Inc will post -2.72 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. purchased a new position in Forty Seven in the first quarter valued at about $32,000. BNP Paribas Arbitrage SA purchased a new position in Forty Seven in the first quarter valued at about $48,000. Metropolitan Life Insurance Co NY purchased a new position in Forty Seven in the first quarter valued at about $88,000. New York State Common Retirement Fund purchased a new position in Forty Seven in the fourth quarter valued at about $101,000. Finally, MetLife Investment Advisors LLC purchased a new position in Forty Seven in the first quarter valued at about $122,000. 47.34% of the stock is currently owned by institutional investors.

A number of brokerages recently weighed in on FTSV. Zacks Investment Research upgraded Forty Seven from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Wednesday, May 8th. HC Wainwright set a $21.00 target price on Forty Seven and gave the company a “buy” rating in a report on Tuesday, May 14th. Roth Capital began coverage on Forty Seven in a report on Wednesday, May 29th. They issued a “buy” rating and a $28.00 target price on the stock. Oppenheimer reiterated a “buy” rating on shares of Forty Seven in a report on Tuesday, March 19th. Finally, Guggenheim began coverage on Forty Seven in a report on Friday, April 12th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $26.89.

Forty Seven Company Profile

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

See Also: Trading Ex-Dividend

Insider Buying and Selling by Quarter for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.